Biotechnology is a complex field and investors can face a wild ride during volatile periods – so a highly experienced management team is crucial to success…

IBT remains differentiated to peers, offering exposure to the explosive potential of innovation in healthcare...

Dividend culture as we knew it is dead, according to Kepler's David Johnson, but investment trusts offer a solution...

After dividends were slashed through 2020, the case for income investors to reconsider portfolio allocations and diversifying their sources of income is clear…

IBT has had a change of management - but no change of strategy…

The pandemic has boosted secular growth drivers behind healthcare as an investment theme...

After a vintage year in which healthcare stocks were at the forefront of addressing the coronavirus pandemic, a wave of M&A in the sector promises opportunities for investors…

Download the presentation and listen to the audio from our 'Ideas for your ISA' Spring Conference on 03 March...

Sitting in one of the few sectors to be positively impacted by COVID-19, we look at IBT how it delivers consistently attractive total returns…

IBT offers a differentiated way to access strong growth prospects at an undemanding valuation...

Slides and audio from our event focused on alternative routes to a reliable income…

View the presentation and listen to the audio from our 'Alternatives for Income Investors' event on 29 September...

This trust offers a blend of characteristics which might appeal to many investors...

The acquisition of smaller biotech companies by their larger counterparts has been a tailwind for investors in this high-octane sector...

We meet the team of doctors and medical scientists behind International Biotechnology Trust...

IBT offers a differentiated exposure to a secular growth theme complemented by a solid yield…

Is there something fishy about a trust paying dividends from capital?

With a pandemic sweeping the globe and causing panic in stock markets, investors may be looking for ways to tap into scientific innovation, while also diversifying in the face of a punishing sell-o...

International Biotechnology Trust (IBT) released its interim results this week, amid a rapidly changing landscape for the healthcare sector...

At a time when healthcare is in the headlines, we take a look at the longer-term trends that are driving biotechnology innovation on a global scale...

Two of our analysts discuss the growing trend for companies to pay an income out of capital…

A highly experienced management team and a flexible portfolio of quoted and unquoted biotechnology stocks, with a yield target of 4% of NAV...

We discuss the opportunity as biotech stocks trade at record low valuations, despite strong prospects for the sector...

Chairman of International Biotechnology Trust, John Aston, explains how his unusual background in both biotechnology and banking come together on the trust...

Carl Harald Janson explains how his experiences in science and business blend seamlessly in his management of International Biotechnology Trust...

Five years on from the appointment of a new manager, this US-focused biotech trust has seen its fortunes transformed...

Some investment trust premiums have been stretched to eye-watering levels. Have investors been enjoying themselves in the sun too much? We try to rationalise current levels and suggest alternatives...

We scour the investment trust universe for trusts offering chunky yields on a discount...

A well-resourced biotechnology fund that has produced annualised returns of +18% pa under the current manager, offering a yield of 4%...

Jupiter Fund of Investment Trusts manager Richard Curling gives his view on the potential risks and rewards for the major equity regions around the world in 2018...